ClinicalTrials.gg
RecruitingNCT07733141Updated Oct 16, 2026

Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease

An interventional study of Biospecimen Collection and Mindfulness Relaxation in Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 16, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States — 48 open to participants now, 70 under way, 7 of them phase 3. Bronchiolitis Obliterans Syndrome · United States.

Planned enrollment
206th of 260
17 · median 45
Started
2027
the only one that year
No phase
66 of 300
13 open now
Primary completion
2028-04
later than 43 of 68 live
Registered
298th of 300
by date

Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, this one is the 206th largest by planned enrollment of the 260 interventional ones that give a count, is the only one that started in 2027, is one of 66 with no phase, reaches primary completion later than 43 of the 68 other live ones, and was the 298th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

48 of the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, or all of them as a file.
02

Study summary

This clinical trial tests a mindfulness intervention, consisting of group sessions and an individual session, using mindfulness based stress reduction techniques, to reduce patient reported symptoms for patients with chronic graft versus host disease (cGVHD). In patients undergoing allogeneic stem cell transplant, sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). In cGVHD patients may encounter stiffness, itching, joint and muscle pain, oral cavity pain, itchy eyes, shortness of breath, depression, anxiety, and poor sleep resulting in a significant impact on patients' quality of life. Mindfulness interventions use meditation practices with elements of psychology to improve emotional regulation, resilience and acceptance based coping. This mindfulness based intervention may reduce patient reported symptoms in patients with cGVHD.

Read the detailed description

PRIMARY OBJECTIVE:

I. Assess the feasibility of an 8-week mindfulness-based intervention (MBI) program consisting of weekly group sessions and a practitioner/patient 1:1 session in patients with a diagnosis of chronic graft-versus-host disease (cGVHD).

SECONDARY OBJECTIVES:

I. Determine the number of patients who withdraw consent before starting group sessions or do not attend any of the planned group sessions.

II. Assess the feasibility of daily self-meditation in patients with a diagnosis of cGVHD.

III. Estimate the preliminary efficacy of the MBI program in patients with cGVHD.

EXPLORATORY OBJECTIVE:

I. Examine potential associations between the MBI program and the following at baseline, Week 4, and at completion of the MBI program.

OUTLINE:

Patients complete group sessions once weekly (QW), on weeks 1-4, over 40 minutes, and on weeks 6-8, over 60 minutes, and an individual session, over 60 minutes, on week 5. Sessions consist of instruction on diaphragmatic breathing, body scan, visualization, and individual mediation practice. Patients are recommended to complete self mediation daily for at least 15 minutes, for 8 weeks. Patients undergo blood sample collection throughout the study.

03

Conditions studied

  • Chronic Graft Versus Host Disease
  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative
  • Willingness to participate in the study
  • Willingness to attend in-person or virtual group sessions
  • Ability to read and understand English (required for protocol therapy and planned survey)
  • Age: ≥ 18 years
  • Confirmed diagnosis of moderate/severe chronic by National Institute of Health (NIH) criteria
  • performance status ≥ 80

Exclusion criteria

Exclusion Criteria:

  • Previous participation in four or more sessions of mindfulness-based cognitive therapy (MBCT)/ mindfulness-based stress reduction (MBSR)
  • An increase in anti-cGvHD medication (increased dosage or addition of a new medication) within 4 weeks prior to baseline evaluation
  • Severe psychiatric comorbidities (active psychosis, suicidal ideation) as determined by primary investigator (PI)
  • Concurrent , disease, chronic infections, or other chronic inflammatory illness that might confound the results as determined by the PI
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (estimated)

Study arms

  • Experimental
    Supportive care (mindfulness based intervention)

    Patients complete group sessions QW, on weeks 1-4, over 40 minutes, and on weeks 6-8, over 60 minutes, and an individual session, over 60 minutes, on week 5. Sessions consist of instruction on diaphragmatic breathing, body scan, visualization, and individual mediation practice. Patients are recommended to complete self mediation daily for at least 15 minutes, for 8 weeks. Patients undergo blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Behavioral: Mindfulness Relaxation · Other: Survey Administration

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • BehavioralMindfulness Relaxation

    Complete group mindfulness sessions

    Also known as: MBSR, Mindful Meditation, Mindfulness Meditation, Mindfulness-Based Stress Reduction

  • BehavioralMindfulness Relaxation

    Complete individual mindfulness session

    Also known as: MBSR, Mindful Meditation, Mindfulness Meditation, Mindfulness-Based Stress Reduction

  • BehavioralMindfulness Relaxation

    Complete daily self meditation

    Also known as: MBSR, Mindful Meditation, Mindfulness Meditation, Mindfulness-Based Stress Reduction

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Compliance (feasibility)

    Feasibility is defined as 12 or more of 15 evaluable participants meet compliance criteria. Compliance for each participant will be a binary endpoint (yes versus no). If a participant completes 5/7 group sessions, the practitioner/patient 1:1 session, and end of treatment assessments, compliance is defined as yes. Will be summarized using the percentage and 90% confidence intervals.

    Time frame: Up to 8 weeks

Secondary outcomes

  1. Reason for not starting study activities after signing consent

    For participants who withdraw consent before starting group sessions or do not attend any of the planned group sessions, the reason for not starting study activities after signing consent will be recorded for each patient

    Time frame: Up to 8 weeks

  2. Feasibility of daily meditation in patients with a diagnosis of cGVHD

    Feasibility of daily meditation will be assessed weekly and will be defined as 4/7 days per week in which the participant logged at least 15 minutes of individual meditation

    Time frame: Up to 8 weeks

  3. Decrease of > 5 points on the 7-day Modified Lee Chronic Graft Versus Host Disease Symptom Scale (MLSS

    Participants will self-report the level of distress they experienced in the previous week for each of the 28-items on a scale of 0 to 4, with 0 representing "not at all", 1 "slightly", 2 "moderately", 3 "quite a bit", and 4 "extremely". Items will be added to create a total score, which can range from 0 to 100, with a higher score indicating a higher overall symptom burden

    Time frame: From baseline to completion of mindfulness based intervention (MBI) program, up to 8 weeks

  4. Decrease in cGVHD severity stage per 2014 NIH consensus cGVHD grading criteria

    Decrease of one full organ stage (e.g., Stage 1 to Stage 2), or a clear functional change like a 2-point P-ROM score shift per 2014 NIH consensus cGVHD grading criteria

    Time frame: From baseline to completion of MBI program, up to 8 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Apr 2028, 13 months later.

Of 110 non-industry interventional studies with no phase under Bronchiolitis Obliterans Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 13 months is below that.

Counting every sponsor, half of 122 studies reached it within 22 months; a quarter within 11 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Mar 2029 → Apr 2028 and completion Mar 2029 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 29, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Apr 8, 2028was Mar 2029
CompletionEst.
Apr 8, 2028was Mar 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
City of Hope Medical Center is now Recruiting
Oct 16, 2026
Primary completion
Mar 1, 2029→Apr 8, 2028
Oct 16, 2026
Study completion
Mar 1, 2029→Apr 8, 2028
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    City of Hope Medical Center is now Recruiting
    Primary completion Mar 1, 2029→Apr 8, 2028
    Study completion Mar 1, 2029→Apr 8, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07733141
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Apr 8, 2028 (estimated)
Completion
Apr 8, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Amandeep Salhotra
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion